Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented promising clinical data from its Bria-IMT™ regimen at the 2023 American Association for Cancer Research Annual Meeting. Of the 18 patients studied since 2021, 15 remain alive, showcasing a significant survival benefit compared to typical outcomes in similar cohorts. The treatment demonstrated effective immune system activation, especially in patients with advanced metastatic breast cancer who had failed prior therapies. The data indicates improved progression-free survival (PFS) rates and a tolerable safety profile. BriaCell is also advancing Bria-OTS2.0, an enhanced version of its personalized immunotherapy, which shows potential for greater clinical efficacy. The ongoing studies aim to further validate these findings and address the unmet needs in metastatic breast cancer treatment.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the Board's approval of a reorganization to spin-out its pre-clinical pipeline assets, including Bria-TILsRx™ and PKCδ inhibitors, into a new entity termed SpinCo. This move aims to enhance shareholder value by allowing independent development of SpinCo Assets. Upon closing, BriaCell shareholders will receive shares in both BriaCell and SpinCo, with 33.33% ownership of SpinCo. Dr. William V. Williams will lead SpinCo. The transaction requires approval from 66.67% of BriaCell's shareholders and court authorization, aiming to attract funding for the further advancement of SpinCo’s assets.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. These presentations will showcase updated survival data and new patient insights related to immunotherapies for cancer. Key topics include the use of whole cell antigen presenting immune stimulating cells for metastatic breast cancer, and engineering cancer vaccines. The abstracts will be published on April 14, 2023, in the Cancer Research journal.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) reports promising survival data from its Phase II trial of Bria-IMT™ combined with Incyte’s retifanlimab for advanced metastatic breast cancer. Of 11 patients treated in 2021/2022, 9 (82%) remain alive, showcasing significant survival benefits. The regimen has shown tolerability without dose-limiting toxicities. Additionally, 7 of 11 patients experienced disease control or progression-free survival, with a median progression-free survival of 3.5 months. The FDA has agreed to use survival as the primary endpoint for the upcoming pivotal trial. BriaCell also announced the enrollment of 9 additional patients, building on the 12 already in the study.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) held its annual general and special meeting on February 9, 2023, where 6,663,370 common shares, representing 42.94% of the total shares, were voted. Shareholders approved all proposed resolutions, which included appointing MNP LLP as auditors, electing new directors, and approving the new omnibus equity incentive plan. The Omnibus Plan is pending final approval from the Toronto Stock Exchange. A formal report of the voting results will be filed on SEDAR.